baricitinib

Details

Generic Name:
baricitinib
Project Status:
Pending
Therapeutic Area:
Alopecia areata, severe
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Olumiant
Project Line:
Reimbursement Review
Project Number:
SR0843-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with severe alopecia areata.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with severe alopecia areata.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.